Biden administration’s $3.2 billion antiviral pandemic plan is fizzling out

Taking stock of the drug industry, from the lab to the medicine chest

August 26, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Karen Dias for STAT STAT+ | Biden administration's $3.2 billion antiviral pandemic plan is fizzling out An ambitious effort to develop antiviral medications is seen to be at risk of becoming "half a bridge to nowhere." By Jason Mast STAT+ | Tome Biosciences files notice to lay off virtually entire staff In a legal notice filed Friday in Massachusetts, the gene-editing startup said it would lay off nearly its entire staff of 130 employees. By Jason Mast STAT+ | Continuous glucose monitoring for the masses is here. Are we ready for it? Continuous glucose monitors, which significantly improved the lives of diabetes patients, are about to become more widely accessible. By Katie Palmer and Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser